Orthopedic Biomaterials Market Report Suite for Australia | 2016 – 2022 | MedSuite | Bone Graft Substitute, Hyaluronic Acid Viscosupplementation, Bone Growth Factors

Orthopedic Biomaterials Market Report Suite for Australia | 2016 – 2022 | MedSuite | Bone Graft Substitute, Hyaluronic Acid Viscosupplementation, Bone Growth Factors


Bone graft substitutes are designed to fill bone voids, which eliminates the need for autograft harvesting of the patient’s own bone. Viscosupplementation products are injected directly into the affected knee joint to relieve pain caused by osteoarthritis. Growth factors are naturally occurring molecules in the body that mediate various cellular functions.

  • Year: 2016
  • Scope: 2012-2022
  • Region: Australia
  • Published Date: 03/01/2016
  • Pages: 107
  • Type: MedSuite

Major Segments Covered in the Orthopedic Biomaterials Market Report Suite

Overall, the Australian orthopedic biomaterials market totaled $47.1 million in 2015 with a high-single digit growth rate. The market is expected to maintain its long-term growth trajectory through 2022.

The Australian orthopedic biomaterials market consists of bone graft substitutes (BGSs), hyaluronic acid (HA) viscosupplementation and growth factors (i.e. bone morphogenetic protein).

While this report suite contains all Australian Orthopedic Biomaterials data, each of the markets are also available as stand alone MedCore reports. This allows you to get access to only the Orthopedic Biomaterials market research that you need. You can view all these included reports and segmentation here:

  • Australian Market Overview for Orthopedic Biomaterials 2016 – MedView: Gives an easily accessible view of all orthopedic biomaterials markets and trends, and aggregates the data together for a picture of the total Australian market.
  • Australian Procedure Numbers for Orthopedic Biomaterials 2016 – MedPro: Using a number of databases, internal and external, we’re able to provide you with the total volume of orthopedic biomaterials procedures being performed for each of the markets mentioned in this suite of reports.
  • Australian Market Report for Bone Graft Substitutes 2016 – MedCore: Bone is a biologically active tissue and will regenerate whenever possible; however, there are instances where the damage is significant enough to warrant a scaffold to help rejoin the fissure or cavity. Bone grafting is a surgical procedure in which damaged bone is replaced with autograft tissue, allograft tissue or a bone graft substitute, which can be either synthetic or metal.
  • Australian Market Report for Hyaluronic Acid Viscosupplementation 2016 – MedCore: Hyaluronic acids (HAs) are naturally occurring biopolymer fluids found in the joints that help cushion them from wear. Sufferers of osteoarthritis are deficient in these fluids. One of the treatment options for these patients is HA viscosupplement injections. Viscosupplements are injectable products that come in three varieties of injection regimens. The market consisted of two segments, single-injection and three-injection, with single-injection.
  • Australian Market Report for Orthopedic Growth Factors 2016 – MedCore: Growth factors are a group of small, soluble proteins that bind onto cell surface receptors, triggering a series of signals that regulate the body’s ability to grow, renew and heal. Due to the regenerative properties of growth factors, they have been exploited for bone healing in orthopedic applications.


Buying all of these reports together in this suite package will provide you with substantial discounts from the separate prices. Request Pricing to Learn More

Orthopedic Biomaterials Market Trends

The orthopedic biomaterials market in Australia grew in-line with its historical growth but slower than in the previous two years. This is mainly due to the entry of major new products and their consecutive hyper growth in the period of 2012 to 2014. In fact, all three segments of the orthopedic biomaterials market had one major new product introduced during that period.

The fastest growing segment in 2015 was hyaluronic acid viscosupplementation. The second best performing segment in 2015 was bone graft substitutes. This segment consists of three sub-segments: allografts, synthetics and demineralized bone matrices (DBM). The allograft and synthetic sub-segments largely performed in-line with their historical trends, while DBM continued to outperform them due to the recent entry of the very first commercial product in Australia.

To read more about the Australian orthopedic biomaterials market trends, take a look at our latest Expert Article from our Analysts:

Medtronic, DePuy Synthes, Wright Medical Compete With Local Manufacturers in Asia-Pacific Orthopedic Biomaterials Market

Orthopedic Biomaterials Report Data Types Included

  • Unit Sales, Average Selling Prices, Market Value & Growth Trends
  • Forecasts Until 2022, and Historical Data to 2012
  • Market Drivers & Limiters for Each Orthopedic Biomaterials Segment
  • Competitive Analysis with Market Shares for Each Segment
  • Recent Mergers & Acquisitions
  • Orthopedic Biomaterials Procedure Volumes
  • Disease Overviews and Demographic Information
  • Company Profiles, Product Portfolios for Top Competitors
  • Related Press Releases from Top Competitors

Orthopedic Biomaterials Companies Analyzed

Based in Dublin, Ireland, Medtronic is one of the world’s largest medical device companies and has two offices in Australia located at North Ryde and Lane Cover, both suburbs of Sydney. Medtronic sells two versions of its synthetic MasterGraft® product: a compressible matrix block and putty, as well as an HAP-based Nanostim® that comes in a paste form. These products complement the hardware lineup offered Medtronic’s highly competitive spinal fusion department.

DePuy Synthes is a multinational orthopedic and neuro product company, which is owned by Johnson & Johnson. Its main office in Australia is located in North Ryde, a suburb of Sydney. In the Australian biologics market, DePuy Synthes gained the second largest share in that segment. It also introduced the first commercial DBM product in Australia marketed as DBX®.

The Australian Orthopedic Biomaterials Market Report Suite includes analysis on the following companies currently active in this market:
Austofix, Austspine, Baxter, Bioventus, Bone Banks, Cerapedics, DePuy Synthes, Emergo Asia Pacific, Genzyme (Sanofi), Global Orthopaedic, LMT Surgical, Medtronic, Nuvasive, Prism Surgical, Scient’x Australia, Signature Orthopaedics and other.

Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.

History of Our Orthopedic Biomaterials Market Research

We’ve been doing market research for medical devices for over a decade. We specialize in it, and the orthopedic biomaterials market was one of our original reports that helped build trust in our research and methodology. We have built relationships with the top competitors in the orthopedic biomaterials market so that we can gather proprietary information in confidence to assure more accurate research – that our partners and clients then benefit from.

Because we’re a third party researcher, we have the ability to reach well into the top orthopedic device companies and look at a multi-angle approach to our research. Not only do we consider financial filings, we conduct interviews, use hospital and procedural databases, and our own history of research to create a picture of the market that’s incredibly accurate.

Our clients have used our orthopedic biomaterials market research for years to strategize new markets to break into, submit SEC filings, decide sales and marketing strategies, plan acquisitions and product launches, and provide a 3rd party source to show investors, boards, and senior executives.

The "Australian Market Report Suite for Orthopedic Biomaterials 2016 - MedSuite" includes analysis on the following companies currently active in this market:
Bone Banks
DePuy Synthes
Emergo Asia Pacific
Genzyme (Sanofi)
Global Orthopaedic
LMT Surgical
Prism Surgical Designs
Scient'x Australia
Signature Orthopaedics
Smith & Nephew
Surgiplas Medical
Wright Medical
Zimmer Biomet

*Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology

Not Exactly What You Need?

Subscribe to MedTech Market News - Get exclusive analyst articles, monthly newsletters and iData offers